Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
9FzwECJQ9vX75TYN
